Brandon Capital

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.

Respirion Pharmaceuticals is an early-stage biotechnology company established in 2018 that specializes in developing innovative treatments for respiratory diseases, particularly Cystic Fibrosis. Originating as a spinout from the Telethon Kids Institute in Perth, the company has focused on creating an inhaled therapy that combines the antibiotic tobramycin with an adjuvant designed to disrupt bacterial biofilms in the lungs. This approach aims to enhance the efficacy of antibiotics and improve patient outcomes in combating lung infections associated with Cystic Fibrosis. The company's lead product has demonstrated promising results in initial clinical trials, which were conducted in collaboration with the Western Australian Department of Health. To advance its research and clinical trials further, Respirion has formed partnerships with prominent organizations, including Australia’s Medical Research Commercialisation Fund and the US Cystic Fibrosis Foundation.

Cincera Therapeutics Pty Ltd is a privately held biotechnology company based in Mawson Lakes, Australia, established in 2017. The company specializes in the discovery and development of small molecule drugs aimed at treating challenging inflammatory and fibrotic conditions linked to obesity, metabolic disorders, and cancer. Cincera's innovative approach focuses on creating effective therapies that address difficult-to-treat diseases, including applications for liver problems and other related health issues, ultimately enabling healthcare providers to improve patient outcomes.

MycRx is a drug development company based in Melbourne, Australia, focused on creating innovative treatments for cancer and new antibiotics with unique mechanisms of action. The company utilizes its proprietary hit identification technology to develop small molecule inhibitors targeting cMyc, a protein implicated in over 50% of human cancers. These inhibitors aim to regulate the oncoprotein associated with various types of cancer, including blood, melanoma, pancreatic, lung, breast, cervical, prostate, colon, stomach, bladder, and brain cancers, thereby enhancing patient outcomes. Founded in 2013 by a team with extensive experience in the pharmaceutical and biotech sectors, MycRx collaborates with the Peter MacCallum Cancer Centre and CSIRO to advance its research and development efforts. In 2015, the company secured a $5 million investment from the MRCF and CSIRO to support its initiatives.

Aravax is an early-stage biotechnology company based in Melbourne, Australia, dedicated to developing a safe and effective treatment for peanut allergies. Founded in May 2015 through the acquisition of intellectual property from Alfred Health and Monash University, Aravax employs proprietary technology aimed at resetting the immune system to tolerate peanuts without triggering allergic reactions. The company's innovative approach seeks to eliminate the risk of life-threatening responses to peanuts, allowing patients to undergo treatment and potentially overcome mild symptoms such as itchiness, rash, and gastrointestinal upset.

OncoRes Medical is an early-stage medical device company based in Perth, Western Australia, focused on developing an innovative imaging technology that enhances intraoperative surgical procedures. This technology, which employs a novel combination of optical coherence tomography, aims to improve surgical accuracy and reduce complication rates during breast cancer surgeries by providing real-time information that helps surgeons distinguish between tumor and healthy tissue. In collaboration with leading researchers from the University of Western Australia and the Harry Perkins Institute of Medical Research, as well as breast cancer surgeons within the Western Australian public health system, OncoRes Medical is advancing its patent-protected technology. The company is supported by funding from the Medical Research Commercialisation Fund, with the goal of transforming the standard of care in clinical applications that require detailed assessment of tissue microstructure.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a primary cause of dry eye disease (DED). The company's portfolio includes a range of compounds designed to address the underlying causes of MGD and improve health outcomes for individuals suffering from ocular surface diseases, where effective treatment options are limited. Azura utilizes a novel drug delivery platform to enhance the efficacy of its therapies. The company is headquartered in Tel Aviv-Yafo, Israel, with operational presence in Australia and the United States, and is supported by a management team experienced in the development and commercialization of novel ocular treatments.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.

Cincera Therapeutics Pty Ltd is a privately held biotechnology company based in Mawson Lakes, Australia, established in 2017. The company specializes in the discovery and development of small molecule drugs aimed at treating challenging inflammatory and fibrotic conditions linked to obesity, metabolic disorders, and cancer. Cincera's innovative approach focuses on creating effective therapies that address difficult-to-treat diseases, including applications for liver problems and other related health issues, ultimately enabling healthcare providers to improve patient outcomes.

Q-Sera Pty Ltd specializes in developing innovative blood collection tubes that enhance the efficiency of blood clotting, utilizing snake venom-derived proteins. This technology accelerates the clotting process, allowing for the rapid production of high-quality serum essential for biochemical analysis and clinical diagnostics. The company's approach leverages potent prothrombin activators isolated from the venom of certain snakes, including the Australian Taipan. These proteins are manufactured through modified cell lines using standard pharmaceutical processes, ensuring reliability and effectiveness. By improving the speed and quality of serum production, Q-Sera's technology aims to optimize laboratory efficiency and enhance patient care.

Certa Therapeutics, established in 2017 and headquartered in Melbourne, Australia, is a biotechnology company specializing in the development of precision medicines for fibrotic diseases, with a primary focus on kidney disorders. The company employs genetic analysis to identify patients at risk of developing kidney fibrosis, a precursor to end-stage kidney failure. Certa's drug pipeline targets a key receptor driving kidney fibrosis, aiming to halt or reverse the scarring process and prevent the need for dialysis or transplantation. Currently in the clinical stage, the company's mission is to transform the treatment landscape for fibrotic diseases by enabling early intervention and improving patient outcomes.

Global Kinetics Corporation Limited, founded in 2007 and based in Melbourne, Australia, specializes in mobile health technology aimed at managing patients with Parkinson's disease and other movement disorders. The company focuses on developing innovative solutions for the monitoring and quantification of movement symptoms associated with neurological diseases. Its primary product, the PKG Data Logger, is a wrist-worn device that automatically records movement data, providing valuable insights to healthcare professionals for diagnosing and treating movement disorders. The technology was developed by a team including Professor Malcolm Horne and Dr. Rob Griffiths from the Florey Institute of Neuroscience & Mental Health, the largest neuroscience research group in Australia.

Cincera Therapeutics Pty Ltd is a privately held biotechnology company based in Mawson Lakes, Australia, established in 2017. The company specializes in the discovery and development of small molecule drugs aimed at treating challenging inflammatory and fibrotic conditions linked to obesity, metabolic disorders, and cancer. Cincera's innovative approach focuses on creating effective therapies that address difficult-to-treat diseases, including applications for liver problems and other related health issues, ultimately enabling healthcare providers to improve patient outcomes.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a primary cause of dry eye disease (DED). The company's portfolio includes a range of compounds designed to address the underlying causes of MGD and improve health outcomes for individuals suffering from ocular surface diseases, where effective treatment options are limited. Azura utilizes a novel drug delivery platform to enhance the efficacy of its therapies. The company is headquartered in Tel Aviv-Yafo, Israel, with operational presence in Australia and the United States, and is supported by a management team experienced in the development and commercialization of novel ocular treatments.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.

Elastagen is a clinical stage medical company focused on developing products derived from the human protein tropoelastin, which is essential for the elasticity and resilience of various tissues in the body, including skin and blood vessels. The company has created a synthetic version of elastin that mimics the natural protein found in humans. Its advanced product pipeline targets applications in skin rejuvenation, scar remodeling, and tissue repair. With injectable synthetic human elastin and chemically cross-linked tropoelastin for aesthetic uses, Elastagen aims to help patients maintain skin elasticity and suppleness. Founded after acquiring intellectual property rights to elastin technology developed by Professor Weiss at the University of Sydney, Elastagen has successfully secured funding from prominent life science venture capital firms and expanded its operations to include production in Europe and clinical activities in the UK.

Aravax is an early-stage biotechnology company based in Melbourne, Australia, dedicated to developing a safe and effective treatment for peanut allergies. Founded in May 2015 through the acquisition of intellectual property from Alfred Health and Monash University, Aravax employs proprietary technology aimed at resetting the immune system to tolerate peanuts without triggering allergic reactions. The company's innovative approach seeks to eliminate the risk of life-threatening responses to peanuts, allowing patients to undergo treatment and potentially overcome mild symptoms such as itchiness, rash, and gastrointestinal upset.

Global Kinetics Corporation Limited, founded in 2007 and based in Melbourne, Australia, specializes in mobile health technology aimed at managing patients with Parkinson's disease and other movement disorders. The company focuses on developing innovative solutions for the monitoring and quantification of movement symptoms associated with neurological diseases. Its primary product, the PKG Data Logger, is a wrist-worn device that automatically records movement data, providing valuable insights to healthcare professionals for diagnosing and treating movement disorders. The technology was developed by a team including Professor Malcolm Horne and Dr. Rob Griffiths from the Florey Institute of Neuroscience & Mental Health, the largest neuroscience research group in Australia.

OccuRx is a Melbourne-based biopharmaceutical company founded in 2014, focusing on the development of innovative therapeutic strategies for ophthalmic disorders linked to retinal fibrosis. The company aims to address the unmet clinical need for targeted ocular therapies through its proprietary small-molecule drugs, which are designed to enhance visual acuity and prevent vision loss in inflammatory and degenerative eye diseases. OccuRx's strategies enable healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce inflammation in the retina, thereby improving patient outcomes in the treatment of these conditions.

MycRx is a drug development company based in Melbourne, Australia, focused on creating innovative treatments for cancer and new antibiotics with unique mechanisms of action. The company utilizes its proprietary hit identification technology to develop small molecule inhibitors targeting cMyc, a protein implicated in over 50% of human cancers. These inhibitors aim to regulate the oncoprotein associated with various types of cancer, including blood, melanoma, pancreatic, lung, breast, cervical, prostate, colon, stomach, bladder, and brain cancers, thereby enhancing patient outcomes. Founded in 2013 by a team with extensive experience in the pharmaceutical and biotech sectors, MycRx collaborates with the Peter MacCallum Cancer Centre and CSIRO to advance its research and development efforts. In 2015, the company secured a $5 million investment from the MRCF and CSIRO to support its initiatives.

Heart Metabolics Limited is focused on developing a pharmaceutical therapy for hypertrophic cardiomyopathy (HCM), a condition characterized by the thickening of the heart muscle, which can lead to heart failure and sudden death. With over 100,000 cases in the United States, HCM often presents more severely in younger individuals, particularly athletes. While existing cardiovascular drugs offer some relief, many patients do not benefit from current treatments. Heart Metabolics is advancing perhexiline, a drug already approved in Australia and New Zealand for angina, as a potential therapy for all forms of HCM. Following encouraging results from phase II clinical trials, the company is preparing to conduct further clinical trials in the U.S. and aims to obtain FDA approval for perhexiline as an orphan drug, a designation it already holds. Through this development, Heart Metabolics seeks to address significant unmet medical needs in HCM treatment.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Auspherix Pty Ltd. is an early-stage anti-infectives company based in Stevenage, United Kingdom, focused on the discovery and development of organogold-based antibiotics aimed at treating serious and challenging infections that may be life-threatening. Established in 2013, the company is working to advance its novel antibiotic candidates through pre-clinical and clinical development stages. To facilitate this progress, Auspherix is seeking additional investment and industry partnerships to support the broad-spectrum application of its innovative therapies.

G I Therapies is a Melbourne-based company founded in 2012 that specializes in developing non-invasive medical devices aimed at treating gastrointestinal motility disorders. The company's primary focus is on chronic constipation, a condition affecting both adults and children, as well as related issues such as irritable bowel syndrome with constipation and gastroparesis. By commercializing innovative technologies, G I Therapies seeks to enhance the quality of life for patients suffering from these disorders, providing effective solutions that promote better gastrointestinal health.

Q-Sera Pty Ltd specializes in developing innovative blood collection tubes that enhance the efficiency of blood clotting, utilizing snake venom-derived proteins. This technology accelerates the clotting process, allowing for the rapid production of high-quality serum essential for biochemical analysis and clinical diagnostics. The company's approach leverages potent prothrombin activators isolated from the venom of certain snakes, including the Australian Taipan. These proteins are manufactured through modified cell lines using standard pharmaceutical processes, ensuring reliability and effectiveness. By improving the speed and quality of serum production, Q-Sera's technology aims to optimize laboratory efficiency and enhance patient care.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Vaxxas is a biotechnology company based in Brisbane, Australia, that specializes in developing a needle-free vaccination technology aimed at transforming vaccine delivery. The company's innovative system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This approach allows for direct deposition of vaccines among a dense concentration of immune cells in the skin. Additionally, Vaxxas utilizes proprietary dry-coating technology to minimize or eliminate the need for refrigeration during the storage and transport of vaccines, thereby alleviating the logistical challenges associated with maintaining the cold chain. Founded in 2011, Vaxxas aims to enhance global vaccination efforts through its novel delivery system.

Signostics Limited is a medical technology company based in Clovelly Park, Australia, that specializes in the development and manufacture of portable point-of-care devices for both medical and veterinary markets. The company's flagship products include the SignosRT Bladder Scanner, which utilizes ultrasound technology to detect the bladder and calculate its volume, and the SignosRT Handheld Ultrasound, designed to assist clinicians in their examinations. These devices cater to a variety of applications, including hospital medicine, family practice, remote healthcare, and physical therapy. Established in 2005, Signostics has expanded its reach internationally, with regulatory approvals for its products in the United States, Europe, and Australia. The company also maintains offices in Palo Alto, California, and continues to focus on delivering innovative and accessible medical solutions through a network of global distributors.

Signostics Limited is a medical technology company based in Clovelly Park, Australia, that specializes in the development and manufacture of portable point-of-care devices for both medical and veterinary markets. The company's flagship products include the SignosRT Bladder Scanner, which utilizes ultrasound technology to detect the bladder and calculate its volume, and the SignosRT Handheld Ultrasound, designed to assist clinicians in their examinations. These devices cater to a variety of applications, including hospital medicine, family practice, remote healthcare, and physical therapy. Established in 2005, Signostics has expanded its reach internationally, with regulatory approvals for its products in the United States, Europe, and Australia. The company also maintains offices in Palo Alto, California, and continues to focus on delivering innovative and accessible medical solutions through a network of global distributors.

Fibrotech Therapeutics focuses on developing innovative drug candidates aimed at treating fibrosis related to various chronic conditions. The company's research and development efforts are directed towards addressing diseases such as diabetic nephropathy, kidney diseases, heart failure, pulmonary fibrosis, and arthritis. Founded in 2006 and based in Wonga Park, Australia, Fibrotech Therapeutics is dedicated to improving patient outcomes through its targeted therapeutic solutions.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.